<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344563</url>
  </required_header>
  <id_info>
    <org_study_id>YSP-RBH3012-03</org_study_id>
    <nct_id>NCT02344563</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Two Formulations of Meropenem Intravenous Injection</brief_title>
  <official_title>A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Meropenem In Healthy Volunteers(Meropenem Intravenous Injection) After Intravenous Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yung Shin Pharm. Ind. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yung Shin Pharm. Ind. Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two&#xD;
      formulations of meropenem (meropenem intravenous injection 0.5 g) after intravenous infusion&#xD;
      in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and incidences</measure>
    <time_frame>predose to 6 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>pre dose to 6 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Meropem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5g/vial,one vial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mepem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.25g/vial ,two vials</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropem</intervention_name>
    <arm_group_label>Mepem</arm_group_label>
    <arm_group_label>Meropem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepem</intervention_name>
    <arm_group_label>Mepem</arm_group_label>
    <arm_group_label>Meropem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult male or female subjects between 20-45 years of age.&#xD;
&#xD;
          -  Body weight within 80-120% of ideal body weight and higher than or equal to 50 kg for&#xD;
             male subjects and 45 kg for female subjects.&#xD;
&#xD;
               -  Ideal body weight (kg) = [height (cm) - 80] × 0.7 for male subjects&#xD;
&#xD;
               -  Ideal body weight (kg) = [height (cm) - 70] × 0.6 for female subjects&#xD;
&#xD;
          -  Acceptable medical history and physical examination including:&#xD;
&#xD;
        no particular clinically significant abnormality in X-ray and ECG results within six months&#xD;
        prior to study. no particular clinical significance in general disease history within two&#xD;
        months prior to study.&#xD;
&#xD;
          -  Acceptable vital signs (within normal limits or considered by the investigator or&#xD;
             physician to be of no clinical significance) at screening, which includes pulse rate,&#xD;
             blood pressure and body temperature.&#xD;
&#xD;
          -  Acceptable clinical chemistry determinations (within normal limits or considered by&#xD;
             the investigator or physician to be of no clinical significance) within two months&#xD;
             prior to study, which includes AST (SGOT), ALT (SGPT), γ-GT, alkaline phosphatase,&#xD;
             total bilirubin, albumin, glucose, BUN, uric acid, creatinine, total cholesterol and&#xD;
             triglyceride (TG).&#xD;
&#xD;
          -  Acceptable hematology (within normal range or considered by the investigator or&#xD;
             physician to be of no clinical significance) within two months prior to study, which&#xD;
             includes hemoglobin, hematocrit, red blood cell count, white blood cell count with&#xD;
             differentials and platelets.&#xD;
&#xD;
          -  Acceptable urinalysis (within normal limits or considered by the investigator or&#xD;
             physician to be of no clinical significance) within two months prior to study, which&#xD;
             includes pH, blood, glucose, ketones, bilirubin and protein.&#xD;
&#xD;
          -  Female subjects of childbearing potential practicing an acceptable method of birth&#xD;
             control from at least seven days prior to study until the end of study as judged by&#xD;
             the investigator(s) or surgically sterile (bilateral tubal ligation, bilateral&#xD;
             oophorectomy or hysterectomy performed on the subject).&#xD;
&#xD;
          -  Have signed the written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A clinically significant disorder involving the cardiovascular, respiratory, hepatic,&#xD;
             renal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s)&#xD;
             or psychiatric disease (as determined by the clinical investigator).&#xD;
&#xD;
          -  A clinically significant illness or surgery within four weeks prior to study (as&#xD;
             determined by the investigator).&#xD;
&#xD;
          -  History of gastrointestinal obstruction, inflammatory bowel disease, gallbladder&#xD;
             disease, pancreas disorder over last two years or history of gastrointestinal tract&#xD;
             surgery over last five years.&#xD;
&#xD;
          -  History of kidney disease or urination problem over last two years deemed by the&#xD;
             investigator to be clinically significant.&#xD;
&#xD;
          -  Known or suspected history of drug abuse within lifetime as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  History of alcohol addiction or abuse within last five years as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  Have a personal history or family history of drug allergy.&#xD;
&#xD;
          -  Subjects demonstrating a positive meropenem skin test screen prior to the study.&#xD;
&#xD;
          -  Evidence of chronic or acute infectious diseases.&#xD;
&#xD;
          -  Female subjects demonstrating a positive urine pregnancy screen prior to study.&#xD;
&#xD;
          -  Female subjects who are currently breastfeeding.&#xD;
&#xD;
          -  Taking any drug known to induce or inhibit hepatic drug metabolism within four weeks&#xD;
             prior to study. Examples of inducers include: piperidines, carbamazepine,&#xD;
             dexamethasone and rifampin. Examples of inhibitors include: cimetidine,&#xD;
             diphenhydramine, fluvastatin, methadone and ranitidine.&#xD;
&#xD;
          -  Taking any prescription medications within four weeks or any nonprescription&#xD;
             medications (excluding flu vaccination) within two weeks prior to study.&#xD;
&#xD;
          -  Use of any investigational drug within four weeks prior to study.&#xD;
&#xD;
          -  Donating more than 250 mL of blood within two months prior to study or donating plasma&#xD;
             (e.g. plasmapheresis) within two weeks prior to study.&#xD;
&#xD;
          -  Any other medical reason as determined by the clinical investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Yuan Shi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>zyshi@vghtc.gov.tw</affiliation>
  </overall_official>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>January 22, 2015</last_update_submitted>
  <last_update_submitted_qc>January 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

